Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement (NASDAQ:VNDA)

Vanda Pharmaceuticals' revenue growth is driven by Fanapt's label expansion to bipolar I disorder. Check out why I maintain a Buy rating on VNDA stock.